@DrAbdulRazak_MD @JNogMD @kaashif_ahmad @EBNEO @M_Aboud84 @rehman_naveed Will be interesting to see if an NI trial in higher risk subpops follows. This a scenario where efficacy data for standard of care exists (https://t.co/D2ex1GV7wc), so would be hard t
@abbvie @Irishprems @NICUchat Cochrane review - Palivizumab reduces RSV admissions of premature infants. http://t.co/6CaQ3nsn0n Roy Philip
MT @ukcochranecentr: #CochraneEvidence that palivizumab prophylaxis reduces hospitalizations due to #RSV in children http://t.co/Pu7yin4UHq
MT @ukcochranecentr: #CochraneEvidence that palivizumab prophylaxis reduces hospitalizations due to #RSV in children http://t.co/Pu7yin4UHq
MT @ukcochranecentr: #CochraneEvidence that palivizumab prophylaxis reduces hospitalizations due to #RSV in children http://t.co/Pu7yin4UHq
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane review. http://t.co/6mqsMB2rn9
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane review. http://t.co/rEeePSvdI9